New molecular targets (ARF GTPases) can improve early diagnosis of prostate cancer and prediction of its progression
Prostate cancer (PCa) is the most common cancer in men (excluding non melanoma skin cancer) in the UK with over 40,000 cases diagnosed each year (CancerResearchUK [2015]). However, for some men with early stage PCa that is confined to the prostate the disease may never be life threatening and can follow and indolent course which…